_id
691054c8ccc777a4e85d5591
Ticker
CRL
Name
Charles River Laboratories
Exchange
NYSE
Address
251 Ballardvale Street, Wilmington, MA, United States, 01887
Country
USA
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD
Website
https://www.criver.com
Description
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. In additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington
Last Close
194.43
Volume
225728
Current Price
194.71
Change
0.14401069793756166
Last Updated
2025-11-29T11:51:13.402Z
Image
-
Ipo Date
2000-06-23T00:00:00.000Z
Market Cap
8767244288
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9612970588235294
Sentiment Sources
34
Rating
3.3158
Target Price
188.9333
Strong Buy
4
Buy
0
Hold
14
Sell
0
Strong Sell
1
Current Quarter
2025-09-30
Revenue
1004852000
Cost Of Revenue
666060000
Gross Profit
338792000
Operating Expenses
204993000
Operating Income
133799000
Interest Expense
25403000
Pretax Income
87200000
Net Income
54422000
Eps
1.1010804030267471
Dividends Per Share
-
Shares Outstanding
49215471
Income Tax Expense
31644000
EBITDA
197767000
Operating Margin
13.315294192577614
Total Other Income Expense Net
-46599000
Cash
207670000
Short Term Investments
-
Receivables
734482000
Inventories
302550000
Total Current Assets
1532104000
Property Plant Equipment
1965898000
Total Assets
7513812000
Payables
169615000
Short Term Debt
2636000
Long Term Debt
2185453000
Total Liabilities
4062995000
Equity
3405449000
Depreciation
85164000
Change In Working Capital
-5145000
Cash From Operations
213826000
Capital Expenditures
35580000
Cash From Investing
-33696000
Cash From Financing
-152616000
Net Change In Cash
24480000
PE
-
PB
2.828071659273124
ROE
1.5980858911702982
ROA
0.7242928090295578
FCF
178246000
Fcf Percent
0.17738532639632504
Piotroski FScore
4
Health Score
59
Deep Value Investing Score
6
Defensive Investing Score
6
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
5.5
Growth Investing Score
3
Momentum Investing Score
3.5
Net Net Investing Score
2.5
Quality Investing Score
5.5
Value Investing Score
6
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
1004852000
Quarters > 0 > income Statement > cost Of Revenue
666060000
Quarters > 0 > income Statement > gross Profit
338792000
Quarters > 0 > income Statement > operating Expenses
204993000
Quarters > 0 > income Statement > operating Income
133799000
Quarters > 0 > income Statement > interest Expense
25403000
Quarters > 0 > income Statement > pretax Income
87200000
Quarters > 0 > income Statement > net Income
54422000
Quarters > 0 > income Statement > eps
1.1010804030267471
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
49426000
Quarters > 0 > income Statement > income Tax Expense
31644000
Quarters > 0 > income Statement > EBITDA
197767000
Quarters > 0 > income Statement > operating Margin
13.315294192577614
Quarters > 0 > income Statement > total Other Income Expense Net
-46599000
Quarters > 0 > balance Sheet > cash
207670000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
734482000
Quarters > 0 > balance Sheet > inventories
302550000
Quarters > 0 > balance Sheet > total Current Assets
1532104000
Quarters > 0 > balance Sheet > property Plant Equipment
1965898000
Quarters > 0 > balance Sheet > total Assets
7513812000
Quarters > 0 > balance Sheet > payables
169615000
Quarters > 0 > balance Sheet > short Term Debt
2636000
Quarters > 0 > balance Sheet > long Term Debt
2185453000
Quarters > 0 > balance Sheet > total Liabilities
4062995000
Quarters > 0 > balance Sheet > equity
3405449000
Quarters > 0 > cash Flow > net Income
55556000
Quarters > 0 > cash Flow > depreciation
85164000
Quarters > 0 > cash Flow > change In Working Capital
-5145000
Quarters > 0 > cash Flow > cash From Operations
213826000
Quarters > 0 > cash Flow > capital Expenditures
35580000
Quarters > 0 > cash Flow > cash From Investing
-33696000
Quarters > 0 > cash Flow > cash From Financing
-152616000
Quarters > 0 > cash Flow > net Change In Cash
24480000
Quarters > 0 > ratios > PE
1.1010804030267471
Quarters > 0 > ratios > PB
2.828071659273124
Quarters > 0 > ratios > ROE
1.5980858911702982
Quarters > 0 > ratios > ROA
0.7242928090295578
Quarters > 0 > ratios > FCF
178246000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.17738532639632504
Quarters > 0 > health Score
59
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
1032135000
Quarters > 1 > income Statement > cost Of Revenue
675068000
Quarters > 1 > income Statement > gross Profit
357067000
Quarters > 1 > income Statement > operating Expenses
256933000
Quarters > 1 > income Statement > operating Income
100134000
Quarters > 1 > income Statement > interest Expense
29967000
Quarters > 1 > income Statement > pretax Income
71418000
Quarters > 1 > income Statement > net Income
52326000
Quarters > 1 > income Statement > eps
1.0610349582285667
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
49316000
Quarters > 1 > income Statement > income Tax Expense
18725000
Quarters > 1 > income Statement > EBITDA
220892000
Quarters > 1 > income Statement > operating Margin
9.701637867139473
Quarters > 1 > income Statement > total Other Income Expense Net
-28716000
Quarters > 1 > balance Sheet > cash
182824000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
767569000
Quarters > 1 > balance Sheet > inventories
279550000
Quarters > 1 > balance Sheet > total Current Assets
1469862000
Quarters > 1 > balance Sheet > property Plant Equipment
1992489000
Quarters > 1 > balance Sheet > total Assets
7560545000
Quarters > 1 > balance Sheet > payables
145798000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
2332374000
Quarters > 1 > balance Sheet > total Liabilities
4160959000
Quarters > 1 > balance Sheet > equity
3353321000
Quarters > 1 > cash Flow > net Income
52693000
Quarters > 1 > cash Flow > depreciation
119507000
Quarters > 1 > cash Flow > change In Working Capital
11167000
Quarters > 1 > cash Flow > cash From Operations
204603000
Quarters > 1 > cash Flow > capital Expenditures
35298000
Quarters > 1 > cash Flow > cash From Investing
-37339000
Quarters > 1 > cash Flow > cash From Financing
-226921000
Quarters > 1 > cash Flow > net Change In Cash
-46988000
Quarters > 1 > ratios > PE
1.0610349582285667
Quarters > 1 > ratios > PB
2.865642705842954
Quarters > 1 > ratios > ROE
1.5604232341610003
Quarters > 1 > ratios > ROA
0.6920929641976867
Quarters > 1 > ratios > FCF
169305000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.16403377465157173
Quarters > 1 > health Score
58
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
984168000
Quarters > 2 > income Statement > cost Of Revenue
666436000
Quarters > 2 > income Statement > gross Profit
317732000
Quarters > 2 > income Statement > operating Expenses
243063000
Quarters > 2 > income Statement > operating Income
74669000
Quarters > 2 > income Statement > interest Expense
27884000
Quarters > 2 > income Statement > pretax Income
35978000
Quarters > 2 > income Statement > net Income
25469000
Quarters > 2 > income Statement > eps
0.5008357422374294
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
50853000
Quarters > 2 > income Statement > income Tax Expense
10100000
Quarters > 2 > income Statement > EBITDA
184226000
Quarters > 2 > income Statement > operating Margin
7.587017663650922
Quarters > 2 > income Statement > total Other Income Expense Net
-38691000
Quarters > 2 > balance Sheet > cash
229356000
Quarters > 2 > balance Sheet > short Term Investments
63000
Quarters > 2 > balance Sheet > receivables
756629000
Quarters > 2 > balance Sheet > inventories
290156000
Quarters > 2 > balance Sheet > total Current Assets
1506358000
Quarters > 2 > balance Sheet > property Plant Equipment
1989977000
Quarters > 2 > balance Sheet > total Assets
7582366000
Quarters > 2 > balance Sheet > payables
149334000
Quarters > 2 > balance Sheet > short Term Debt
0
Quarters > 2 > balance Sheet > long Term Debt
2510754000
Quarters > 2 > balance Sheet > total Liabilities
4340584000
Quarters > 2 > balance Sheet > equity
3194336000
Quarters > 2 > cash Flow > net Income
25878000
Quarters > 2 > cash Flow > depreciation
120364000
Quarters > 2 > cash Flow > change In Working Capital
1287000
Quarters > 2 > cash Flow > cash From Operations
171697000
Quarters > 2 > cash Flow > capital Expenditures
59324000
Quarters > 2 > cash Flow > cash From Investing
-45479000
Quarters > 2 > cash Flow > cash From Financing
-105325000
Quarters > 2 > cash Flow > net Change In Cash
26158000
Quarters > 2 > ratios > PE
0.5008357422374294
Quarters > 2 > ratios > PB
3.102025103808742
Quarters > 2 > ratios > ROE
0.7973175019785019
Quarters > 2 > ratios > ROA
0.3358977923249814
Quarters > 2 > ratios > FCF
112373000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.1141807089846449
Quarters > 2 > health Score
47
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1002549000
Quarters > 3 > income Statement > cost Of Revenue
718305000
Quarters > 3 > income Statement > gross Profit
284244000
Quarters > 3 > income Statement > operating Expenses
451931000
Quarters > 3 > income Statement > operating Income
-167687000
Quarters > 3 > income Statement > interest Expense
28234000
Quarters > 3 > income Statement > pretax Income
-216791000
Quarters > 3 > income Statement > net Income
-215699000
Quarters > 3 > income Statement > eps
-4.217978802456099
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
51138000
Quarters > 3 > income Statement > income Tax Expense
-3044000
Quarters > 3 > income Statement > EBITDA
-86453000
Quarters > 3 > income Statement > operating Margin
-16.726065259653144
Quarters > 3 > income Statement > total Other Income Expense Net
-49104000
Quarters > 3 > balance Sheet > cash
194606000
Quarters > 3 > balance Sheet > short Term Investments
62000
Quarters > 3 > balance Sheet > receivables
720915000
Quarters > 3 > balance Sheet > inventories
278544000
Quarters > 3 > balance Sheet > total Current Assets
1403071000
Quarters > 3 > balance Sheet > property Plant Equipment
2016504000
Quarters > 3 > balance Sheet > total Assets
7528345000
Quarters > 3 > balance Sheet > payables
140337000
Quarters > 3 > balance Sheet > short Term Debt
0
Quarters > 3 > balance Sheet > long Term Debt
2240205000
Quarters > 3 > balance Sheet > total Liabilities
4020267000
Quarters > 3 > balance Sheet > equity
3461503000
Quarters > 3 > cash Flow > net Income
-213747000
Quarters > 3 > cash Flow > depreciation
102104000
Quarters > 3 > cash Flow > change In Working Capital
-42396000
Quarters > 3 > cash Flow > cash From Operations
159362000
Quarters > 3 > cash Flow > capital Expenditures
75616000
Quarters > 3 > cash Flow > cash From Investing
-76104000
Quarters > 3 > cash Flow > cash From Financing
-75879000
Quarters > 3 > cash Flow > net Change In Cash
-6070000
Quarters > 3 > ratios > PE
-4.217978802456099
Quarters > 3 > ratios > PB
2.878646602935199
Quarters > 3 > ratios > ROE
-6.2313682813506155
Quarters > 3 > ratios > ROA
-2.8651582784795333
Quarters > 3 > ratios > FCF
83746000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.0835330741938798
Quarters > 3 > health Score
32
Valuation > metrics > PE
1.1010804030267471
Valuation > metrics > PB
2.828071659273124
Valuation > final Score
100
Valuation > verdict
44.5% Undervalued
Profitability > metrics > ROE
1.5980858911702982
Profitability > metrics > ROA
3.5521087341329314
Profitability > metrics > Net Margin
0.05415921946714541
Profitability > final Score
22
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.1930864329490767
Risk > metrics > Interest Coverage
5.2670550722355625
Risk > final Score
51
Risk > verdict
High
Liquidity > metrics > Current Ratio
8.894601482719985
Liquidity > metrics > Quick Ratio
7.138153044104243
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
68.97974896191258
Prev Valuations > 2
80
Prev Profitabilities > 0
21
Prev Profitabilities > 1
11
Prev Profitabilities > 2
0
Prev Risks > 0
43
Prev Risks > 1
41
Prev Risks > 2
6
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-12T15:39:52.735Z
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. In additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACharles River (NYSE: CRL) names 6 firms to cell & gene therapy incubator, opens 2026 apps Stock Titan
Read more →Invesco Ltd. Purchases 128,785 Shares of Charles River Laboratories International, Inc. $CRL MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
HOLD
Target Price:
$188.9333
Analyst Picks
Strong Buy
4
Buy
0
Hold
14
Sell
0
Strong Sell
1
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 103.82% of the total shares of Charles River Laboratories
1.
Vanguard Group Inc(11.8091%)
since
2025/06/30
2.
Wellington Management Company LLP(7.6559%)
since
2025/06/30
3.
BlackRock Inc(7.429%)
since
2025/06/30
4.
Allspring Global Investments Holdings, LLC(4.6554%)
since
2025/06/30
5.
State Street Corp(3.7769%)
since
2025/06/30
6.
Vanguard Health Care Inv(3.6606%)
since
2025/06/30
7.
Allspring Special US Mid Cap Value Eq(3.5981%)
since
2025/06/30
8.
Allspring Mid Value SMA(3.5981%)
since
2025/06/30
9.
Allspring Special Mid Cap Value Inst(3.4481%)
since
2025/07/31
10.
Nomura Holdings Inc(3.1887%)
since
2025/06/30
11.
Vanguard Total Stock Mkt Idx Inv(3.1403%)
since
2025/07/31
12.
Ariel Investments, LLC(2.8759%)
since
2025/06/30
13.
Amvescap Plc.(2.5138%)
since
2025/06/30
14.
Geode Capital Management, LLC(2.5038%)
since
2025/06/30
15.
Vanguard 500 Index Investor(2.4713%)
since
2025/07/31
16.
Vanguard Small Cap Index(2.4224%)
since
2025/07/31
17.
Harris Associates L.P.(2.363%)
since
2025/06/30
18.
Bank of America Corp(2.0848%)
since
2025/06/30
19.
Dimensional Fund Advisors, Inc.(2.0537%)
since
2025/06/30
20.
Mackenzie Investments(2.0361%)
since
2025/06/30
21.
Vanguard Windsor Investor Shares(2.0321%)
since
2025/06/30
22.
Earnest Partners LLC(2.0284%)
since
2025/06/30
23.
Invesco S&P 500® Equal Weight ETF(1.9027%)
since
2025/08/29
24.
Vanguard Small Cap Value Index Inv(1.5546%)
since
2025/07/31
25.
Morgan Stanley - Brokerage Accounts(1.5338%)
since
2025/06/30
26.
UBS Group AG(1.494%)
since
2025/06/30
27.
SEI Investments Co(1.4522%)
since
2025/06/30
28.
Neuberger Berman Group LLC(1.4116%)
since
2025/06/30
29.
Oakmark Select Investor(1.3777%)
since
2025/06/30
30.
Invesco S&P 500 ETF(1.3752%)
since
2025/07/31
31.
Fidelity 500 Index(1.2651%)
since
2025/07/31
32.
D. E. Shaw & Co LP(1.2334%)
since
2025/06/30
33.
Cooke & Bieler LP(1.2167%)
since
2025/06/30
34.
SPDR® S&P 500® ETF(1.2082%)
since
2025/08/31
35.
iShares Core S&P 500 ETF(1.201%)
since
2025/08/31
36.
Ariel Fund Investor(1.1377%)
since
2025/06/30
37.
Canada Life US Small-Mid Cap Growth F(0.8963%)
since
2025/06/30
38.
EARNEST Partners Smid Cap Core Founders(0.8781%)
since
2025/08/31
39.
The Health Care Select Sector SPDR® ETF(0.6815%)
since
2025/08/31
40.
Mackenzie US Mid Cap Opportunities F(0.6565%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.